AFT Pharmaceuticals is considering the impact of a High Court judgment that could see 35% of profits from a drug under development go toward a subsidiary's shareholder.
Yesterday, the Auckland High Court upheld ‘parts’ of claims against publicly listed AFT Pharmaceuticals lodged by
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
